Overview

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Status:
Unknown status

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers

Phase:

Phase 3

Details

Lead Sponsor:

The University of Hong Kong

Collaborator:

Janssen, LP